Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
Compass Pathways reported positive 26-week data from the second pivotal Phase 3 COMP006 trial of COMP360, confirming a durable benefit for treatment-resistant depression. Results showed 39% of participants on the 25mg dose maintained a clinically meaningful response through week 26, with a safety profile consistent with previous studies and no new safety findings.
Key figures
- Drug Name
- COMP360 (psilocybin)
- Phase Of Trial
- Phase 3
- Sae 1mg
- 6.3%
- Sae 25mg
- 5.7%
- Participants comp006
- 581
- Response rate 25mg 6mo
- 39%
- Remission rate responders
- nearly 30%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.